A retrospective comparison found different palliative medication patterns in interstitial pneumonia and lung cancer.
The investigators reviewed patients who died in one hospital. Interstitial-pneumonia patients more often received continuous morphine with midazolam, and their midazolam doses were higher than those of lung-cancer patients. Survival after morphine initiation was shorter in the interstitial-pneumonia group.
Physicians selected treatment, and symptom assessment was not uniform. The study involved people already approaching death. It cannot determine whether a medication shortened survival or whether more severe terminal symptoms prompted additional medication.
An end-of-life causation opinion must distinguish treatment of distress from the disease process leading to death. Review the symptom trajectory, indication, titration, response, and care goals. Comparing survival after a treatment starts does not isolate the treatment’s causal effect when initiation depends on worsening illness.
Source reviewed: Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy (PMC8244508). This article summarizes the supplied paper; forensic applications above are interpretive analysis.
Related reading: Matched Liver Donors Still Produced Different Midazolam Clearance Estimates in Two Lab Systems; Pediatric Dexmedetomidine–Midazolam Meta-Analysis Pooled Different Procedures and Comparators.